Champions Oncology, Inc. (CSBR) vs Kalaris Therapeutics Inc. (KLRS)
Champions Oncology, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Champions Oncology, Inc. and Kalaris Therapeutics Inc. are of similar size ($68.9M and $67.1M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −1.87%) and the higher return on invested capital (0.00% vs −626.2%). Across the 14 metrics below, Kalaris Therapeutics Inc. leads on 8 and Champions Oncology, Inc. on 6.
Valuation
Profitability
| Metric | CSBR | KLRS | Biotechnology median |
|---|---|---|---|
| Gross margin | 49.82% | 0.00% | 65.16% |
| Operating margin | (1.68%) | 0.00% | 0.00% |
| Net margin | (1.87%) | 0.00% | 0.00% |
| Free cash flow margin | (10.08%) | 0.00% | 0.00% |
| Return on equity | (28.38%) | (79.91%) | (57.72%) |
| Return on assets | (3.56%) | (46.02%) | (49.22%) |
| Return on invested capital | (626.23%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack